°í¿ë·® ½ºÅ×·ÎÀ̵å Ä¡·á ÀúÇ×¼º ÆóÃâÇ÷ ·çǪ½º ȯÀÚ¿¡¼ Rituximab »ç¿ë 1¿¹
A Case of Rituximab Therapy in Diffuse Alveolar Hemorrhage of Systemic Lupus Erythematosus Refractory to Steroid Pulse Therapy
´ëÇÑ·ù¸¶Æ¼½ºÇÐȸÁö 2014³â 21±Ç 4È£ p.201 ~ p.204
ÀÓ»ó¿ì(Yim Sang-Woo) - µ¿¾Æ´ëÇб³ ÀÇ°ú´ëÇÐ µ¿¾Æ´ëÇб³º´¿ø ³»°úÇб³½Ç
º¯Ã¢±Ô(Byon Chang-Kyoo) - µ¿¾Æ´ëÇб³ ÀÇ°ú´ëÇÐ µ¿¾Æ´ëÇб³º´¿ø ³»°úÇб³½Ç
¹ÚÁØ¿ë(Park Jun-Yong) - µ¿¾Æ´ëÇб³ ÀÇ°ú´ëÇÐ µ¿¾Æ´ëÇб³º´¿ø ³»°úÇб³½Ç
ÀÌ»ó¿±(Lee Sang-Yeob) - µ¿¾Æ´ëÇб³ ÀÇ°ú´ëÇÐ µ¿¾Æ´ëÇб³º´¿ø ³»°úÇб³½Ç
Á¤¿øÅÂ(Chung Won-Tae) - µ¿¾Æ´ëÇб³ ÀÇ°ú´ëÇÐ µ¿¾Æ´ëÇб³º´¿ø ³»°úÇб³½Ç
Abstract
Rituximab is a chimeric murine-human monoclonal anti-body that is directed against the specific B-cell CD20 anti-gen, which has recently been successfully used in active or refractory systemic lupus erythematosus (SLE) manifes-tations, such as nephritis, thrombocytopenia, and vasculitis. We report a case of a 25-year-old woman diagnosed with diffuse alveolar hemorrhage of SLE refractory to steroid pulse therapy. The patient was treated successfully with rit-uximab as a part of the immunosuppressive regimen.
Å°¿öµå
Rituximab, Diffuse alveolar hemorrhage, Systemic lupus erythematosus
KMID :
0388220140210040201
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)